Authorities maintain the number of blood clots associated with the AstraZeneca vaccine is no greater than the background incidence of the condition.Credit:Stuart Layt
Associate Professor Christopher Blyth,who co-chairs the Australian Technical Advisory Group on Immunisation,told a parliamentary COVID Committee hearing that the rate of death for people who experience the clotting disorder is low – just 3 per cent – and the risk of dying of clotting after receiving the AstraZeneca vaccine is one in 2 million.
Two women have died from the clotting disorder thrombosis with thrombocytopenia in Australia. But an important factor for the group’s decision was the long-term harm that will be experienced by some of the 58 other people who experienced the condition.
“More needs to be considered than deaths,and importantly,more than deaths were considered in our advice of last week,” Dr Blyth said.
“A number of Australians have been harmed as a result of blood clots,and they are particularly occurring in young individuals … a number of those individuals will have long term complications as a result of these events.”
As of last Thursday,36 people diagnosed with thrombosis with thrombocytopenia had been discharged from hospital,but four remained in intensive care.
To date,more than 6.59 million vaccine doses have been administered across the country,including about 4 million doses of AstraZeneca. Lieutenant-General John Frewen,head of Operation Covid Shield,told the committee the country had 2.3 million doses of Pfizer on hand,and a further 3.4 million across the rest of June and July.
Earlier on Monday,the Lieutenant-General briefed the meeting of federal,state and territory leaders on planning for the vaccine rollout to the end of the year.